基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

Treatment · Chronic granulomatous disease

PM359

The first prime-editing therapy given to human patients, with published evidence that it restored the immune function those patients lacked.

Phase I/II prime editingex vivofirst-in-humanNCF1
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

简单说明

Patients with this rare immune disorder have white blood cells that can catch bacteria but cannot kill them. PM359 takes the patient's own blood stem cells, uses prime editing to repair the exact mutation causing the fault, and returns them. In the first patients treated, the repaired cells took hold and the missing immune function came back.

深入了解

PM359 is an autologous CD34+ haematopoietic stem cell therapy in which prime editing corrects the NCF1 delGT mutation causing p47phox-deficient chronic granulomatous disease. Published results from the first two participants, following busulfan conditioning, reported prompt neutrophil and platelet engraftment, 69 and 83 per cent dihydrorhodamine-positive neutrophils by day 30, durable restoration of NADPH oxidase activity and early clinical benefit including resolution of CGD-associated colitis.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

仅供教育参考 本页面为参考资源,不构成医疗建议。研究进展和监管状态会发生变化;请查看上方的最后更新日期,并对重要信息进行核实,以所列主要来源为准。